Radiotherapy Planning Based on Positron Emission Tomography With Fluoro-deoxyglucose For Advanced NSCLC

Conditions

Non-small Cell Lung Cancer

Keywords

NSCLC, FDG-PET, Radiotherapy, planning, target volumes

Brief summary

Simultaneous radio-chemotherapy in advanced non-small cell lung cancer. The study focusses on a randomised comparison of conventional radiotherapy planning with irradiation of macroscopic tumor and lymph nodes together with prophylactic target volumes vs. irradiation only of FDG-positive lesions. Primary endpoint is the local disease control in the chest.

Detailed description

Simultaneous radio-chemotherapy in advanced non-small cell lung cancer. The study focusses on a randomised comparison of conventional radiotherapy planning with irradiation of macroscopic tumor and lymph nodes together with prophylactic target volumes vs. irradiation only of FDG-positive lesions. Primary endpoint is the local disease control in the chest

Dejonckheere CS, Nour Y, Sahlmann J, Engelhart MT, Hammi A, Barth SA, Schimek-Jasch T, Adebahr S, Hecht M, Waller C, Schmid S, Miederer M, Brose A, Binder H, König J, Rimner A, Grosu AL, Nestle U, Gkika E.

2025-04-25

10.1016/j.radonc.2025.110907

Impact of Different Mediastinal Staging Modalities on Target Volume Delineation in Locally Advanced Non-Small Cell Lung Cancer: A Secondary Analysis of the Multicenter Randomized PET-Plan Trial.

Rimner A, Dejonckheere CS, Sahlmann J, Barth SA, Schimek-Jasch T, Adebahr S, Hecht M, Waller CF, Schmid S, Stolz D, Miederer M, Brose A, Binder H, König J, Grosu AL, Nestle U, Gkika E.

2025-03-051 citations

10.1016/j.ijrobp.2025.02.041

Impact of mediastinal tumor burden and lymphatic spread in locally advanced non-small-cell lung cancer: A secondary analysis of the multicenter randomized PET-Plan trial.

Gkika E, Dejonckheere CS, Sahlmann J, Barth SA, Schimek-Jasch T, Adebahr S, Hecht M, Miederer M, Brose A, Binder H, König J, Grosu AL, Nestle U, Rimner A.

2024-09-033 citations

10.1016/j.radonc.2024.110521

Cardiac Function Modifies the Impact of Heart Base Dose on Survival: A Voxel-Wise Analysis of Patients With Lung Cancer From the PET-Plan Trial.

Craddock M, Nestle U, Koenig J, Schimek-Jasch T, Kremp S, Lenz S, Banfill K, Davey A, Price G, Salem A, Faivre-Finn C, van Herk M, McWilliam A.

2022-09-1832 citations

10.1016/j.jtho.2022.09.004

Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial.

Nestle U, Schimek-Jasch T, Kremp S, Schaefer-Schuler A, Mix M, Küsters A, Tosch M, Hehr T, Eschmann SM, Bultel YP, Hass P, Fleckenstein J, Thieme A, Stockinger M, Dieckmann K, Miederer M, Holl G, Rischke HC, Gkika E, Adebahr S, König J, Grosu AL, PET-Plan study group.

2020-03-12114 citations

10.1016/s1470-2045(20)30013-9

A teaching intervention in a contouring dummy run improved target volume delineation in locally advanced non-small cell lung cancer: Reducing the interobserver variability in multicentre clinical studies.

Schimek-Jasch T, Troost EG, Rücker G, Prokic V, Avlar M, Duncker-Rohr V, Mix M, Doll C, Grosu AL, Nestle U.

2015-02-1023 citations

10.1007/s00066-015-0812-8

Interventions

PROCEDURErestriction of radiotherapy to FDG-PET positive areas only

Restriction of target volumes to areas positive in positron emission tomography using fluoro-deoxy-glucose

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

No

Inclusion criteria

* histologically proved NSCLC * UICC-stage I-III, no resection planned * complete staging \< 6 wks before treatment including cranial CT * ECOG \<3, Karnofsky-Index \>60% * age \> 18 \< * FEV1 \> 1,0 l or \>35% * RT-planning according to protocol feasible * chemotherapy feasible * written informed consent

Exclusion criteria

* neuroendocrine tumors, plain broncho-alveolar-cell ca. * distant metastases, supraclavicular lymph node metastases * malignant pleural effusion * resection of actual tumor performed * inclusion in other study protocol * chemotherapy due to actual tumor before FDG-PET * induction-chemotherapy * acute vena cava superior syndrome * second malignancy other than basalioma * pregnancy, lactation * heart insufficiency NYHA III/IV * pneumoconiosis with active inflammatory changes of mediastinal lymph nodes * acute broncho-pulmonary infection at time of PET-examination

Design outcomes

Primary

Measure	Time frame	Description
time to local progression	actuarial	Time from randomization to first evidence of local progression or last follow up

Secondary

Measure	Time frame	Description
in and out field progression	actuarial	Time from randomization to progression or last follow up
Overall survival	actuarial	Time from randomization to death or last follow up
normal tissue toxicity	actuarial	Time from randomization to death or last follow up

Countries

Germany

Contacts

Primary ContactU. Nestle, Prof.

ursula.nestle@uniklinik-freiburg.de49-761-270

Backup ContactA. L. Grosu, Prof.

anca.grosu@uniklinik-freiburg.de49-761-270

Outcome results

None listed